Acceptance of treatment for latent tuberculosis infection: Prospective cohort study in the United States and Canada

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 4, 2013, Pages 473-479

  Colson, P W ^a   Hirsch Moverman, Y ^a   Bethel, J ^b   Vempaty, P ^c   Salcedo, K ^d   Wall, K ^e   Miranda, W ^f   Collins, S ^g   Horsburgh, C R ^h  

^a Columbia University ^*  (United States)

^b WESTAT   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^e DENVER PUBLIC HEALTH   (United States)

^f NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^g MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^h BOSTON UNIVERSITY   (United States)

Author keywords

Medical care; Mycobacterium tuberculosis; Prospective survey; Public health clinic

Indexed keywords

BCG VACCINE;

ADULT; ASIAN; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; CULTURAL FACTOR; EDUCATION; EMPLOYMENT STATUS; FEMALE; HEALTH SERVICE; HISPANIC; HUMAN; INCOME; KNOWLEDGE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; PATIENT ATTITUDE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; THERAPY ACCEPTANCE; TREATMENT REFUSAL; UNITED STATES;

ACCULTURATION; ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; APPOINTMENTS AND SCHEDULES; ATTITUDE OF HEALTH PERSONNEL; CANADA; CHI-SQUARE DISTRIBUTION; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; LATENT TUBERCULOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT REFUSAL; UNITED STATES; YOUNG ADULT;

EID: 84875475284     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0697     Document Type: Review

References (21)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S24-7.
2. Centers for Disease Control and Prevention. CDC's response to the IOM report: eliminating tuberculosis in the United States. Atlanta, GA, USA: CDC, 200-2.
3. Geiter L, ed. Ending neglect: the elimination of tuberculosis in the United States. Washington DC, USA: National Academy Press, 200-0.
4. Sterling T R, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh C R. Tuberculosis Epidemiologic Studies C. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173: 927-93-1.
5. Horsburgh C R Jr, Goldberg S, Bethel J, et al. Tuberculosis Epidemiologic Studies C. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest 2010; 137: 401-40-9.
6. Parsyan A E, Saukkonen J, Barry M A, Sharnprapai S, Horsburgh C R Jr. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007; 54: 262-26-6.
7. Brassard P, Bruneau J, Schwartzman K, Sénécal M, Menzies D. Yield of tuberculin screening among injection drug users. Int J Tuberc Lung Dis 2004; 8: 988-99-3.
8. Scholten J N, Driver C R, Munsiff S S, et al. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV) infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis 2003; 37: 1686-169-2.
9. Levesque J-F, Dongier P, Brassard P, Allard R. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis 2004; 8: 711-71-7.
10. Bock N N, Metzger B S, Tapia J R, Blumberg H M. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med 1999; 159: 295-30-0.
11. Shukla S J, Warren D K, Woeltje K F, Gruber C A, Fraser V J. Factors associated with the treatment of latent tuberculosis infection among health care workers at a midwestern teaching hospital. Chest 2002; 122: 1609-161-4.
12. Centers for Disease Control and Prevention. Monitoring tuberculosis programs-National Tuberculosis Indicator Project, United States, 2002-2008. MMWR Morb Mortal Wkly Rep 2010; 59: 295-29-8.
13. Gilroy S A, Rogers M A, Blair D C. Treatment of latent tuberculosis infection in patients aged > or = 35 years. Clin Infect Dis 2000; 31: 826-82-9.
14. Centers for Disease Control and Prevention. Recommendations for targeted tuberculin testing and treatment of LTBI. MMWR Morb Mortal Wkly Rep 2000; 49: 1-5-4.
15. Dunckel-Schetter C L, Feinstein L, Call J. UCLA Social Support Inventory (UCLA-SSI). Los Angeles, CA, USA: UCLA, 1986. http://health.psych.ucla.edu/CDS/ files/UCLA%20SSI%201986.doc Accessed December 201-2.
16. Schwarzer R, Dunkel-Schetter C, Kemeny M. The multidimensional nature of received social support in gay men at risk of HIV infection and AIDS. Am J Community Psychol 1994; 22: 319-33-9.
17. McLellan A T, Luborsky L, Woody G E, O'Brien C P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980; 168: 26-3-3.
18. Becker M. The health belief model and personal behavior. Thorofare, NJ, USA: Charles B Slack Inc, 197-4.
19. Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977; 84: 191-21-5.
20. Fishbein M, Ajzen I. Belief, attitude, intention and behavior: an introduction to theory and research. Menlo Park, NJ, USA: Addison-Wesley, 197-5.
21. Ewart C K. Social action theory for a public health psychology. Am Psychol 1991; 46: 931-94-6.